Deciphera Pharmaceuticals Announces Positive Top-line Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) and Updated Results from Phase 1/2 Study of Vimseltinib in TGCT

MOTION Study Met Primary Endpoint with Objective Response Rate (ORR) at Week 25 of 40% Compared to 0% for Placebo (p<0.0001) MOTION Study Met All Key Secondary Endpoints with Statistically Significant and Clinically Meaningful Improvements at...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials